Phase IIb randomized trial of JX-594, a targeted multimechanistic oncolytic vaccinia virus, plus best supportive care (BSC) versus BSC alone in patients with advanced hepatocellular carcinoma who have failed sorafenib treatment (TRAVERSE).
James M. Burke
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Caroline Breitbach
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Richard H. Patt
Consultant or Advisory Role - Jennerex Biotherapeutics
Riccardo Lencioni
Consultant or Advisory Role - Jennerex Biotherapeutics
Michel Homerin
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Jean-Marc Limacher
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Monika Lusky
Employment or Leadership Position - Transgene S.A.
Stock Ownership - Transgene S.A.
Theresa Hickman
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
Lara Longpre
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics
David H. Kirn
Employment or Leadership Position - Jennerex Biotherapeutics
Stock Ownership - Jennerex Biotherapeutics